Summary Herantis Pharma Plc (Herantis Pharma) is a drug development company that offers regenerative medicine for neurodegenerative diseases.The company’s pipeline products include CDNF for amyotrophic lateral sclerosis, CDNF for Parkinson’s disease and lymfactin for secondary lymphedema.
Its lymfactin recovers the damaged lymph system by reconstituting lymphatic vasculature.Herantis Pharma offers CDNF for disease modification in neurodegenerative diseases such as Parkinson’s and ALS.
The company develops drug candidates through late pre-clinical and early clinical stages.It partners with pharmaceutical and biotech companies.
Herantis Pharma is headquartered in Espoo, Finland.
Herantis Pharma Plc (HRTIS) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Alpha Synuclein - Pipeline Review, H1 2020 Summary According to the recently published report ’Alpha Synuclein – Pipeline Review, H1 2020’; Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 57 molecules....
Schizoaffective Disorder Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Schizoaffective Disorder Global Clinical Trials Review, H2, 2020" provides an overview of Schizoaffective Disorder Clinical trials scenario.This report provides top line data relating to the clinical...
Dyskinesia - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H2 2020, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape. Dyskinesia refers to the involuntary nature of muscular...
5-Hydroxytryptamine Receptor 7 - Pipeline Review, H2 2020 Summary 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes....
214 pages •
By Asia Market Information & Development Company
• Sep 2020
China’s demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports &...
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 - Pipeline Review, H2 2020 Summary Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 188.8.131.52) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and...
Iron Deficiency Anemia - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia - Pipeline Review, H2 2020, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape. Anemia is a condition...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.